donanemab   Click here for help

GtoPdb Ligand ID: 8357

Synonyms: donanemab-azbt | Kisunla® | LY-3002813 | LY3002813
Approved drug
donanemab is an approved drug (FDA (2024))
Compound class: Antibody
Comment: Donanemab (LY3002813) is a monoclonal antibody developed from the murine monoclonal mE8-IgG2a [1]. It binds to N-terminally, pyroglutamate-modified amyloid β proteins (abbreviated as Aβp3-x or N3pG) which are found extensively in the amyloid plaques of the brains of Alzheimer's disease (AD) patients. The removal of Aβp3-x was advanced to cliniucal evaluation as a novel mechanism to treat AD.
Classification Click here for help
Compound class Antibody
Approved drug? Yes. FDA (2024)  |  China NMPA (2024)
International Nonproprietary Names Click here for help
INN number INN
10922 donanemab
Synonyms Click here for help
donanemab-azbt | Kisunla® | LY-3002813 | LY3002813
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 892
Other databases
GtoPdb PubChem SID 252166569
Search PubMed clinical trials donanemab
Search PubMed titles donanemab
Search PubMed titles/abstracts donanemab